EGFR and metastatic colorectal cancer: The anti EGFR-antibodies cetuximab and panitumumab represent well-established treatments for metastatic colorectal cancer (CRC), the third most prevalent cancer entity and fourth most common cause of cancer-related death around the world [1, 2].